Saturday 17 October 2026 Export PRGO’s income statement to Excel — free account

Perrigo Company plc

PRGO Healthcare Drug Manufacturers Specialty & Generic

Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.

16.63 0.15 +0.91%

Follow PRGO

Alert me

Market cap: $2.3B
P/E: 0.0×
Fwd P/E: −77.4×
Dividend yield: 6.98%
F-score: 4/9
Altman Z: −0.08
Beneish M: −3.51
Dividend safety: 16/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.11

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.68%

Capital & Financial Ratios $m

Market Cap 2,290.00

Revenue 4,144.90

Net Income (1,734.70)

Free Cash Flow 119.30

Net Debt 2,895.10

Current Ratio 2.32

Debt/Equity 1.31

P/E ratio 0.00

Fwd P/E (77.40)

P/S ratio 0.56

P/B ratio 0.92

Past 5Y EPS Growth —

This Y EPS Growth (20.00%)

Next Y EPS Growth 9.09%

Next Y revenue growth (4.56%)

Next 5Y EPS Growth (0.67%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 8.77%

10-year low 10-year high

P/B against its own 10 years 28.20%

10-year low 10-year high

EV/Sales against its own 10 years 8.77%

10-year low 10-year high

EV/FCF against its own 10 years 79.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 1.16

Annual Dividend Yield 6.98%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.16	0.29 0.29 0.29
2025	1.16	0.29 0.29 0.29 0.29
2024	1.10	0.28 0.28 0.28 0.28
2023	1.09	0.27 0.27 0.27 0.27
2022	1.04	0.26 0.26 0.26 0.26
2021	0.96	0.24 0.24 0.24 0.24
2020	0.90	0.23 0.23 0.23 0.23
2019	0.82	0.19 0.21 0.21 0.21
2018	0.76	0.19 0.19 0.19 0.19
2017	0.64	0.16 0.16 0.16 0.16
2016	0.73	0.15 0.15 0.15 0.15 0.15

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	751	559	532	400
Receivables	740	642	613	710
Inventory	1,141	1,082	1,149	1,065
Other	—	—	273	—
	2,833	2,482	2,797	2,452

	2023	2024	2025	Q'26
Payables	478	495	475	400
ST’ Debt	441	36	37	11
Other	—	—	27	—
	1,586	1,044	1,013	1,055

Compound Annual Growth %

	10y	5y	3y
Sales	4.92%	0.79%	(1.51%)
Cash Flow	1.73%	(17.82%)	(8.10%)
Earnings	0.00%	0.00%	0.00%
Book Value	(11.63%)	(12.29%)	(15.37%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	969	1,023	—	—	—
’25	1,044	1,056	1,043	1,110	4,253
’24	1,082	1,066	1,088	1,138	4,373
’23	1,182	1,193	1,124	1,157	4,656
’22	1,075	1,122	1,100	1,155	4,452
’21	1,010	981	1,043	1,105	4,139
’20	1,083	949	1,003	1,053	4,088

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(114)	83	—	—	—
’25	(64)	76	52	175	239
’24	(1)	10	42	313	363
’23	19	53	125	209	406
’22	79	(17)	59	186	307
’21	0	(82)	344	(105)	156
’20	172	291	63	110	636

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(126)	68	—	—	—
’25	(88)	58	33	151	151
’24	(25)	(18)	49	281	288
’23	(2)	50	94	186	328
’22	83	(43)	14	186	240
’21	(44)	(105)	303	(146)	8
’20	140	265	20	45	470

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.87)	0.53	—	—	—
’25	(0.05)	(0.06)	0.05	(10.22)	(10.29)
’24	0.01	(0.79)	(0.15)	(0.32)	(1.25)
’23	(0.02)	0.06	0.10	(0.24)	(0.09)
’22	(0.02)	(0.48)	(0.37)	(0.09)	(1.04)
’21	0.28	(0.43)	(0.44)	0.24	(0.52)
’20	0.77	0.44	(1.13)	(1.29)	(1.19)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	79.72	63.68	36.28	38.38	40.01	35.34	30.78	26.81	23.89	12.17	Analyst estimates 2026–2028 Powerpack
	High	152.36	91.73	95.93	57.50	63.86	50.90	43.90	40.28	34.60	30.93
People
People	Employees	12,800	10,400	10,600	11,200	11,500	9,900	8,900	9,140	8,379	8,100
	Revenue/emp, $m	0.41	0.48	0.45	0.35	0.36	0.42	0.50	0.51	0.52	0.53
Income, $m
Income, $m	Revenue	5,281	4,946	4,732	3,870	4,088	4,139	4,452	4,656	4,373	4,253
	Gross margin, %	38.86	40.02	38.71	37.05	36.57	34.22	32.69	36.09	35.27	35.14
	EBT	(4,848)	280	291	148	6	259	(139)	(8)	(81)	(1,298)
	EBT margin, %	(91.81)	5.66	6.14	3.82	0.14	6.25	(3.12)	(0.18)	(1.85)	(30.52)
	Net income	(4,013)	120	131	146	(163)	(69)	(141)	(13)	(172)	(1,425)
	Depreciation	432	422	416	392	382	308	338	362	335	347
Per share, $
Per share, $	Revenue	36.85	34.76	34.34	28.46	30.04	30.98	33.10	34.41	31.83	30.71
	Earnings	(28.01)	0.84	0.95	1.07	(1.19)	(0.52)	(1.04)	(0.09)	(1.25)	(10.29)
	Cash flow	4.57	4.91	4.30	2.85	4.67	1.17	2.28	3.00	2.64	1.72
	Capex	1.73	(0.01)	(0.65)	(0.99)	(1.22)	(1.11)	(0.50)	(0.57)	(0.55)	(0.63)
	Free cash flow	6.30	4.90	3.66	1.86	3.45	0.06	1.78	2.42	2.09	1.09
	Book value	41.57	43.36	41.13	42.68	41.55	38.56	36.00	35.24	31.44	21.19
	Shares, m	143	142	138	136	136	134	135	135	137	139
Valuation, ×
Valuation, ×	P/E	0.00	106.77	41.22	47.83	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.35	2.58	1.13	1.82	1.49	1.26	1.06	0.96	0.81	0.45
	P/B	2.08	2.07	0.94	1.21	1.08	1.01	0.98	0.94	0.82	0.66
	EV/Sales	3.33	3.12	1.70	2.59	2.21	1.66	1.85	1.68	1.51	1.18
	EV/FCF	19.47	22.11	15.93	39.69	19.20	856.58	34.38	23.81	22.91	32.83
Cash, $m
Cash, $m	Operating cash flow	655	699	593	388	636	156	307	406	363	239
	Capex	248	(1)	(89)	(135)	(166)	(148)	(68)	(77)	(75)	(88)
	Free cash flow	902	698	504	253	470	8	240	328	288	151
Balance, $m
Balance, $m	Working capital	969	1,384	1,365	1,395	1,752	2,272	1,606	1,247	1,438	1,785
	Total debt	5,797	3,341	3,242	3,369	3,565	3,521	4,107	4,073	3,618	3,640
	Net debt	5,175	2,663	2,691	3,015	2,933	1,656	3,506	3,322	3,059	3,109
	Shareholders’ equity	5,958	6,171	5,668	5,804	5,655	5,152	4,842	4,768	4,319	2,936
Returns, %
Returns, %	ROA	(24.16)	0.94	1.16	1.31	(1.43)	(0.63)	(1.31)	(0.12)	(1.68)	(15.68)
	ROIC	(11.23)	4.23	1.77	1.24	1.93	3.77	0.59	1.17	0.96	(11.60)
	ROE	(49.96)	1.97	2.21	2.55	(2.84)	(1.28)	(2.81)	(0.26)	(3.78)	(39.29)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)	Compare
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
Median of peers	$2.2B	14.9×	16.5×	+33.01%	+194.59%	+49.51%	73.49%	12.18%

All 86 Drug Manufacturers Specialty & Generic stocks →